LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the completion of its offering and sale of $450 million in aggregate principal amount of 2.50% Convertible Senior Notes due 2017 pursuant to a registration statement filed with the Securities and Exchange Commission. This includes the exercise in full by the underwriters of their option to purchase $50 million aggregate principal amount of the notes.
